Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)

US9649377B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Philip Lowe · Whitley Bay, GB
• Hermann Gram · Weil am Rhein, DE
• Thomas Jung · Wien, AT
• Timothy Wright · San Diego, US
• Trevor Mundel · Carlisle, US

Key dates

• Filing date: Jul 28, 2015
• Grant date: May 16, 2017
• Expiry date: Aug 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds such as IL-1β antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.